Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug aims to help kidney patients fight acid and stay strong

NCT ID NCT07355062

Disease control Sponsor: Renibus Therapeutics, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 04, 2026 · Updated 6 times

Summary

This study tests a drug called veverimer in 150 adults with moderate-to-severe chronic kidney disease (CKD) and a condition called metabolic acidosis, where acid builds up in the blood. The goal is to see if the drug can raise blood bicarbonate levels and improve physical function, like standing up from a chair or walking. Participants take the drug or a placebo for 26 weeks, and the study is currently recruiting.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 150 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2026

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Have provided written informed consent prior to participation in the study. * Male or female participants 18 years of age or older. * Diagnosed with CKD (eGFR \< 60 mL/min/1.73m2) and not expected to require renal replacement therapy (dialysis or kidney transplant) throughout the duration of the study. * Within 6 months prior to screening have at least two SBC between 12 and 20 mmol/L, inclusive. If only one historical SBC is available, a second SBC may be drawn on screening visit S1 and analyzed by the local laboratory. * Within screening period have two central laboratory SBC (at least 24 hours apart and more than 4 hours after food) between 12 and 21 mmol/L, inclusive. * Willing to keep food consumption similar to baseline throughout the entire study. * If taking oral alkali therapy, dose has been stable for at least 28 days prior to the start of screening and is expected to remain stable throughout the study. * Women who are of childbearing potential must have a negative pregnancy test and agree to abstinence or to use contraception. Exclusion Criteria: * Any participant deemed by the Investigator to be an inappropriate candidate for PerfO testing (e.g., severe musculoskeletal pain, non-ambulatory status), inability to complete STS5 without support or with a screening STS5 time \< 10 seconds. * History or current diagnosis of: 1. Clinically significant gastroparesis or a history of bariatric surgery. 2. Bowel obstruction, swallowing disorders, severe gastrointestinal disorders, including inflammatory bowel disease, major gastrointestinal surgery including gastrectomy, or known active gastric/duodenal ulcers. 3. Severe recurrent diarrhea or constipation, as assessed by the Investigator. 4. Pernicious anemia, atrophic or autoimmune gastritis, achlorhydria or hypochlorhydria. * Ineligible per REVIVE GastroScreen test. * Use of GI polymer binders or sodium zirconium cyclosilicate within 14 days prior to the start of screening or have an expectation to initiate treatment during the study. * Use of acid reducing drugs, including PPIs, H2RAs or P-CABs within 14 days prior to the start of screening or have an expectation to initiate treatment during the study. Very sporadic use (one time per week or less) may be acceptable, as assessed by the Investigator. * Initiation of GLP-1 receptor agonists within 6 months prior to the start of screening, or expectation to initiate use during the study. Participants that have been on a GLP-1 receptor agonist for more than 6 months and have maintained a stable dose and steady body weight for at least one month prior to the start of screening may be considered for enrollment, upon Medical Monitor review. GLP-1 receptor agonists also should not be started during the study. * Participants that are taking any of the following medications and have not been on a stable dose for at least 14 days prior to the start of screening or have an expectation to change dose during the study: diuretics, non-ophthalmic carbonic anhydrase inhibitors, diabetes drugs, RAAS inhibitors, calcium or magnesium supplements, non-polymer phosphate binders, and SGLT-2 inhibitors. These medications also should not be started during the study. * Active, recurrent, or metastatic malignancy at the start of screening. * History of malignancy, except under the following conditions: 1. Carcinoma in situ (e.g., of the cervix, breast, or bladder) that has been completely excised and shows no evidence of residual disease. 2. Non-melanoma skin cancers (e.g., basal cell carcinoma, squamous cell carcinoma) that have been completely excised and show no evidence of recurrence. 3. Low grade prostate cancer, in the opinion of the Investigator (i.e., no metastasis, Gleason score \< 6), with no significant worsening for \> 6 months prior to the screening visit. 4. Any other malignancy that was treated with curative intent and has been in complete remission for ≥ 5 years prior to the screening visit. * Two or more hospitalizations within 12 months prior to the start of screening or a hospitalization within the last 3 months prior to the start of screening due to fluid overload, heart failure, acute kidney injury (AKI) or electrolyte disorders, including hyperkalemia. Participants that have not been hospitalized within the past 3 months and whose condition is stable may be considered for enrollment. * Screening hemoglobin \< 9 g/dL. * Low bicarbonate value(s) at time of screening that are due to underlying primary respiratory alkalosis. * Investigational medication administration within 28 days prior to start of screening. * Participants that are taking an average of \> 30 units of insulin daily, unless recent (within last 6 months) hemoglobin A1C is \< 6.5%. * History of alcoholism or drug/chemical abuse within 1 year prior to the start of screening, in the opinion of the Investigator. * Current, regular use of inhaled/ingested cannabis/THC products. * Inability to take the IP or otherwise comply with the protocol. * Any medical condition, uncontrolled systemic disease or serious concurrent illness that would significantly decrease study compliance or jeopardize the safety of the participant or affect the validity of the trial results, in the opinion of the Investigator.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CKD are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Acidosis chronic kidney disease metabolic acidosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CKD Metabolic acidosis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    23 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Study Site

    RECRUITING

    Chula Vista, California, 91910, United States

  • Study Site

    RECRUITING

    Los Angeles, California, 90022, United States

  • Study Site

    RECRUITING

    Sacramento, California, 95817, United States

  • Study Site

    RECRUITING

    San Diego, California, 92111, United States

  • Study Site

    RECRUITING

    Aurora, Colorado, 80045, United States

  • Study Site

    RECRUITING

    Edgewater, Florida, 32132, United States

  • Study Site

    RECRUITING

    Margate, Florida, 33063, United States

  • Study Site

    RECRUITING

    Miami Springs, Florida, 33166, United States

  • Study Site

    RECRUITING

    Orlando, Florida, 32806, United States

  • Study Site

    RECRUITING

    Augusta, Georgia, 30904, United States

  • Study Site

    RECRUITING

    Boise, Idaho, 83706, United States

  • Study Site

    RECRUITING

    Chubbuck, Idaho, 83201, United States

  • Study Site

    RECRUITING

    Idaho Falls, Idaho, 83401, United States

  • Study Site

    RECRUITING

    Chicago, Illinois, 60643, United States

  • Study Site

    RECRUITING

    Indianapolis, Indiana, 46202, United States

  • Study Site

    RECRUITING

    Louisville, Kentucky, 40205, United States

  • Study Site

    RECRUITING

    Kansas City, Missouri, 64111, United States

  • Study Site

    RECRUITING

    Fresh Meadows, New York, 11365, United States

  • Study Site

    RECRUITING

    New York, New York, 10016, United States

  • Study Site

    RECRUITING

    Winston-Salem, North Carolina, 27103, United States

  • Study Site

    RECRUITING

    Fort Worth, Texas, 76110, United States

  • Study Site

    RECRUITING

    Houston, Texas, 77054, United States

  • Study Site

    RECRUITING

    San Antonio, Texas, 78212, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.